The pharmaceutical industry and US regulatory bodies have not responded adequately to the increasing level of outsourced manufacturing in countries such as China and India, according to a new white paper by the PEW Health Group. Increased outsourcing and the complex global supply chain create the potential for counterfeit or substandard medicines to enter the supply chain, says the white paper, titled “After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs.” The authors recommend several steps for improving the security of the pharmaceutical supply chain.
http://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Reports/Health/Pew_Heparin_Final_HR.pdf
This is most comprehensive paper on Supply chain and distribution.